Scholz Heinz S, Petru Edgar, Benedicic Christoph, Haas Josef, Tamussino Karl, Winter Raimund
Department of Obstetrics and Gynecology, University of Graz, Auenbruggerplatz 14, Graz, A-8036, Austria.
Gynecol Oncol. 2002 Jan;84(1):43-6. doi: 10.1006/gyno.2001.6462.
We performed a randomized, prospective trial to assess the impact of fibrin glue on the incidence of lymphocysts after systematic pelvic or pelvic and paraaortic lymphadenectomy in patients with gynecologic malignancies.
Ninety-three consecutive patients with gynecologic pelvic malignancies who underwent surgery including pelvic or pelvic and paraaortic lymphadenectomy were randomized during surgery to be treated with fibrin glue or not. Serial computed tomography (CT) scans were performed during follow-up. CT findings of a smooth and thin-walled cavity filled with a water-equivalent fluid, sharply demarcated from its surroundings and without signs of infiltration were interpreted as lymphocysts.
Forty-seven patients (51%) were treated with fibrin glue and 46 (49%) were not. All 93 patients underwent pelvic lymphadenectomy; 15 patients (32%) of the fibrin group and 12 (26%) of the controls also underwent paraaortic lymphadenectomy. We found no significant differences between patients who received fibrin glue and those who did not.
Intraoperative application of fibrin glue did not reduce the rate of postoperative lymphocysts after lymphadenectomy and had no impact on any follow-up parameter. Its use seems not to be indicated in systematic gynecologic pelvic or pelvic and paraaortic lymphadenectomy.
我们进行了一项随机前瞻性试验,以评估纤维蛋白胶对妇科恶性肿瘤患者行系统性盆腔或盆腔及腹主动脉旁淋巴结清扫术后淋巴囊肿发生率的影响。
93例连续接受包括盆腔或盆腔及腹主动脉旁淋巴结清扫术在内手术的妇科盆腔恶性肿瘤患者在手术期间被随机分为接受或不接受纤维蛋白胶治疗。随访期间进行系列计算机断层扫描(CT)。CT表现为一个光滑、薄壁的腔,充满水样液体,与周围组织界限清晰且无浸润迹象,被解释为淋巴囊肿。
47例患者(51%)接受了纤维蛋白胶治疗,46例(49%)未接受。所有93例患者均接受了盆腔淋巴结清扫术;纤维蛋白胶组15例患者(32%)和对照组12例患者(26%)还接受了腹主动脉旁淋巴结清扫术。我们发现接受纤维蛋白胶治疗的患者与未接受治疗的患者之间无显著差异。
术中应用纤维蛋白胶并未降低淋巴结清扫术后淋巴囊肿的发生率,且对任何随访参数均无影响。在系统性妇科盆腔或盆腔及腹主动脉旁淋巴结清扫术中似乎无需使用纤维蛋白胶。